Treatment of childhood cancers has become increasingly successful, with a current overall cure rate of more than 70% (1,2). Second malignant neoplasms, however, are observed in long-term survivors of childhood cancer, with a 15-year cumulative incidence of 3% -5% (3 -6). Secondary cancers are the second leading cause of death, after recurrence, among 5-year survivors of childhood cancer (7). To date, no large studies have analyzed risk factors other than radiation for secondary sarcomas after childhood malignancy. Radiation therapy for childhood tumors has been associated with the development of secondary sarcomas (5, 6, 8) , but the association between secondary sarcomas and other factors -e.g., chemotherapy exposure, age, or family history of cancer -has not been well studied.
secondary cancers should provide clinicians and researchers with valuable information that could be used to develop effective strategies to detect tumors earlier and to reduce the associated morbidities and mortality in cancer survivors. We investigated the incidence of secondary sarcomas among childhood cancer survivors participating in the CCSS and the association between various factors and the risk of developing secondary sarcomas.
Patients and Methods

Description of Cohort
Detailed characteristics of the CCSS cohort of 5-year childhood cancer survivors have been published previously (9) . Briefly, the CCSS is an ongoing study of 14 372 childhood cancer survivors at 26 participating clinical centers in the United States and Canada. Each participating institution identified all patients in this cohort who fulfilled the following eligibility criteria: 1) diagnosis and initial treatment of leukemia, central nervous system malignancy (excluding meningioma and craniopharyngioma), Hodgkin lymphoma, non-Hodgkin lymphoma, neuroblastoma, soft tissue sarcoma, or kidney or bone cancer; 2) diagnosis date between January 1, 1970, and December 31, 1986; 3) age at diagnosis younger than 21 years; and 4) survival of at least 5 years from the date of diagnosis.
The CCSS protocol and contact documents were reviewed and approved by the Human Subjects Committee at each participating institution. Written informed consent was obtained from each participant or proxy. Data used in this analysis were collected from eligible subjects by use of a questionnaire at baseline (1992 -2004) and, if subjects were still alive and contactable, two follow-up questionnaires (the fi rst in the period of 2000 -2003 and the second in the period of 2001 -2004) . Next of kin, typically a parent or spouse, was contacted for those eligible subjects who were known to have died after achieving 5-year survivorship. Cohort exit was defi ned as the date of the last questionnaire or date of participant death, whichever occurred earlier. The questionnaires addressed social and demographic information, medical conditions diagnosed by a physician, health behaviors, cancer recurrence, development of secondary neoplasms, and family history of cancer. Survey questionnaires used in data collection are available for review at the Web site http://www.stjude.org/ccss ; or in Supplementary Files 1 -4 (available online).
For all CCSS participants who signed a medical record release, a detailed summary of exposure to cancer treatment, including chemotherapy, radiation therapy, and surgery, was obtained. Information about exposure to 49 specifi c chemotherapy agents and cumulative dosing on 22 agents was abstracted. Alkylating agent scores were calculated as previously described (10) . In brief, for each alkylating agent, the total dose received in relation to body surface area was calculated for each study subject. A distribution of the doses received by all the subjects was determined for each alkylating agent and then divided into thirds. Each subject was assigned a score of 0, 1, 2, or 3 for each drug, depending on whether the subject received no alkylating agent or fell into the lower, middle, or upper third of each distribution, respectively. Doses of daunorubicin and/or idarubicin per meter squared were multiplied by 3 to approximate an equivalent dose of doxorubicin and then summed with doxorubicin doses to determine cumulative anthracycline exposure, and doses of etoposide and teniposide were summed to determine cumulative epipodophyllotoxin exposure . The cumulative dose of carboplatin was divided by 4 and added to the cisplatin dose to assess exposure to platinum compounds (11) . Radiation therapy data were coordinated through Department of Radiation Physics, The University of Texas M. D. Anderson Cancer Center, Houston (9) .
Identification of Patients With Secondary Sarcoma and Confirmation of Sarcoma
Patients with secondary sarcoma(s) were initially identified through their self-reported history of a second cancer and then further identified through a secondary review of pathology records by the CCSS Pathology Review Center at Columbus Children's Hospital. Data collected included type of secondary sarcoma (including rhabdomyosarcoma, non-rhabdomyosarcoma soft tissue sarcoma, Ewing/primitive neuroectodermal tumor, osteosarcoma, and malignant peripheral nerve sheath tumor) and location(s) of tumors. The sarcoma had to have been diagnosed at least 5 years after the primary cancer diagnosis. All patients with sarcomas identified before February 1, 2005, were included.
To ensure the validity of the analysis, all secondary sarcoma pathology reports were reviewed independently of the CCSS Pathology Review Center by one of this study's physicians (T. Henderson). We used this procedure to confi rm that the secondary primary tumor was histologically distinct from the originally diagnosed childhood cancer and to identify the histology and grade of each secondary sarcoma.
Statistical Methods
Calculation of Standardized Incidence Ratios and Excess
Absolute Risks. Population studies were undertaken by use of the Surveillance, Epidemiology, and End Results (SEER) Program (12). Standardized incidence ratios (SIRs) and excess absolute risks
CONTEXT AND CAVEATS
Prior knowledge
Childhood cancer survivors have an increased risk of secondary sarcomas, but few risk factors have been well studied.
Study design
Long-term prospective study of childhood cancer survivors.
Contribution
Childhood cancer survivors appear to have a more than ninefold increased risk of secondary sarcomas than the general population. Risks were highest among survivors of soft tissue sarcomas.
Implications
Because sarcoma symptoms are often nonspecific, their diagnosis can sometimes be elusive. Clinicians should be alert to any childhood cancer survivor's prior history.
Limitations
The number of patients with secondary sarcomas was small, and so examination of some risk factors was not feasible. All secondary sarcomas and family histories of cancer were self-reported, and so underreporting may have occurred.
Downloaded from https://academic.oup.com/jnci/article-abstract/99/4/300/2522282 by guest on 09 April 2019 (EARs) were calculated by use of age-and sex-specific sarcoma incidence rates. SEER data were used to determine the number of sarcomas expected in a general population cohort with the same age and sex distribution as the CCSS cohort during its years of observation. The standardized incidence ratios were then calculated as the ratios of the observed numbers of cases in the various subgroups of the cohort to the expected numbers. Excess absolute risks were calculated as the difference between the number of observed and expected events divided by the number of personyears and expressed per 100 000 person-years. Of note, men and women were not analyzed separately, although the effect of sex was examined during the modeling process. Poisson regression models were used to calculate standardized incidence ratios, their 95% confidence intervals (CIs), and P values. All statistical tests were two-sided.
Calculation of Cumulative Incidence Rates. Cumulative incidence estimates for sarcoma occurring after the 5-year anniversary of the primary cancer diagnosis were calculated as previously described by Kalbfleisch and Prentice (13) . Sarcoma occurrence was the event of interest, censoring occurred at completion of the most recent CCSS questionnaire, and death was considered to be a competing risk event.
Risk Factor Analysis. Potential risk factors examined for an association with secondary sarcomas included "current" age (i. 1970 -1974, 1975 -1979 , or 1980 -1986) , history of other second malignant neoplasms (yes or no), and family history of cancer (yes or no).
Univariate analysis was performed to evaluate the impact of potential risk factors on the occurrence of secondary sarcomas. Statistically signifi cant associations between the development of secondary sarcomas and various participant characteristics and cancer treatments were examined by use of the Cox regression model [the assumptions of which were tested by use of the methods of Lin et al. (14) and found to hold]. Participants with a secondary sarcoma were compared with the rest of the patient cohort who did not develop a secondary sarcoma. The results of these univariate regression models, coupled with an a priori decision to include variables that were not statistically signifi cant by univariate analysis but were clinically relevant and possibly important when controlling for other exposures, led to the inclusion of 12 covariates (i.e., age at primary diagnosis, sex, primary diagnosis, radiation exposure, chemotherapy exposure, platinum drug dose categories, epipodophyllotoxin dose categories, alkylator drug scores, anthracycline dose categories, history of other second malignant neoplasms, family history of cancer in a primary relative, and treatment era) in a multivariable Cox regression model to assess their simultaneous impact on the time to development of secondary sarcomas.
Standard asymptotic inference methods for Cox regression that were based on the partial likelihood were used to construct 95% confi dence intervals and to carry out two-sided tests of statistical signifi cance (13) .
Results
Description of Patients With Secondary Sarcoma
At the time of this analysis, which began in February 2005, 751 secondary cancers had been reported among the 14 372 CCSS participants. Of these 751 secondary cancers, 108 were confirmed by medical record and pathologic reviews as being independent secondary sarcomas. These 108 sarcomas developed in 104 CCSS participants, four of whom reported both secondary and tertiary sarcomas. The median age at the time of diagnosis of secondary sarcoma was 20 years, and the median time from primary cancer diagnosis was 11 years. As shown in Table 1 , cohort members who had a secondary sarcoma history were similar to those who did not have such a history in terms of age at primary diagnosis, follow-up time, race, sex, and treatment era. However, patients with secondary sarcomas, compared with those without secondary sarcomas, were more likely to have received primary radiation therapy; to have received higher doses of anthracyclines or alkylators; to have a primary diagnosis of soft tissue sarcoma, bone tumor, or Hodgkin lymphoma; to have a family history of cancer; or to have a history of other second cancers.
The characteristics of the patients with secondary sarcomas are described in Table 2 . Although 79% of the patients received radiotherapy as a component of treatment for primary cancer, we could confi rm that only 56% received that radiotherapy to the primary anatomic site of a secondary sarcoma. Secondary tumors were small (i.e., <5 cm) in 32 (56%) of the 57 patients for whom size of the sarcoma was known. Pathologic grade was determined in 45 (42%) of 108 secondary sarcomas, and 23 (51%) of these 45 tumors were high-grade sarcomas. Secondary sarcoma was the cause of death for 39 (66%) of the 59 deceased patients.
Of the 108 secondary sarcomas, pathologic subtype was known in 100 -50 were non-rhabdomyosarcoma soft tissue sarcomas, 19 were malignant peripheral nerve sheath tumors, and 31 were osteosarcomas. Non-rhabdomyosarcoma soft tissue sarcoma subtypes included malignant fi brous histiocytoma (12 tumors), leiomyo sarcoma (seven tumors), fi brosarcoma (six tumors), spindle cell tumor (four tumors), chondrosarcoma (three tumors), synovial cell tumors (two tumors), rhabdoid tumors (two tumors), angiosarcomas (two tumors), epitheloid sarcoma (one tumor), and malignant sarcomas without other subtyping (11 tumors). There were 27 second sarcomas among Hodgkin lymphoma survivors, including 17 non-rhabdomyosarcoma soft tissue sarcomas, fi ve malignant peripheral nerve sheath tumors, three osteosarcomas, and two rhabdomyosarcomas. Only two of the patients with second sarcoma selfreported neurofi bromatosis type 1, of whom one had a primary diagnosis of brain tumor, followed by two distinct malignant peripheral nerve sheath tumors, and the other had a primary diagnosis of Wilms tumor, followed by malignant peripheral nerve sheath tumor.
When we examined family history of cancer in this cohort, 22 (22.0%) of the 104 patients with secondary sarcoma reported a history of cancer among fi rst-degree relatives. Eight of these 22 participants reported fi rst-degree relatives with tumors suggestive of a familial cancer predisposition syndrome. Five patients had siblings with cancers associated with Li -Fraumeni syndrome (15 -18) (three with childhood sarcoma, one with a central nervous system tumor, and one with premenopausal breast cancer), and three patients had parents with medical histories indicative of the syndrome (two had mothers with early breast cancer and one had a father with young adult onset sarcoma). Eleven of the 104 patients with secondary sarcoma reported a family history of more than two independent cancers. Other cancers that were reported included one family member with breast, four with thyroid, one with kidney, one with colon and rectum, one with brain, and one with ovarian cancer, as well as one family member with acute myelogenous leukemia and one with melanoma.
Standardized Incidence Ratio and Excess Absolute Risk Analysis
To determine the risk of secondary sarcoma in the CCSS cohort in relation to the general population, studies were undertaken by using the SEER database. As shown in Table 3 , the risk of sarcoma was more than ninefold higher among childhood cancer survivors than among the general population (SIR = 9.02, 95% CI = 7.44 to 10.93). Risk among survivors who received radiation therapy (SIR = 11.35, 95% CI = 9.12 to 14.12) was higher than that among survivors who did not receive radiation therapy (SIR = 2.68, 95% CI = 2.04 to 6.64). Risk for the development of a secondary sarcoma among survivors who did not receive radiation therapy was also higher than that among the general population. Relative risks (RRs) were highest in survivors of primary cancers at young age (i.e., younger than 4 years), and the relative rates declined with increasing time of follow-up and increasing age at diagnosis. Highest risks, albeit with wide and overlapping confidence intervals, were observed among survivors of soft tissue sarcomas (SIR = 24.7, 95% CI = 16.9 to 36.1), bone cancers (SIR = 10.6, 95% CI = 6.3 to 18.0), Hodgkin lymphoma (SIR = 11.7, 95% CI = 8.0 to 17.1), and renal tumors (SIR = 14.6, 95% CI = 7.8 to 27.1). Individually, each primary childhood cancer diagnosis was associated with increased risk compared with age-adjusted population rates. Excess absolute risk for secondary sarcoma was 32.54 (95% CI = 26.13 to 40.31) per 100 000 person-years of follow-up ( Table 3 ) . Excess absolute risk was increased for both males and females and was highest among those with the longest period of follow-up. Excess absolute risk was highest in survivors diagnosed with their primary cancer at a young age (for ages 1 -3 years, EAR = 38.01, 95% CI = 25.23 to 56.66) and in those survivors diagnosed between ages 8 and 10 years (EAR = 44.69, 95% CI = 25.76 to 75.63). Exposure to radiation therapy was associated with higher absolute risk (EAR = 42.78, 95% CI = 33.58 to 54.24) than nonexposure (EAR = 10.33, 95% CI = 4.00 to 21.76), although unexposed patients still had statistically signifi cantly elevated risk. Family history of a fi rst-degree relative with cancer was associated with an elevated absolute risk (EAR = 50.03, 95% CI = 31.28 to 78.54). Each primary childhood cancer diagnosis was associated with elevated excess absolute risk. The highest excess absolute risks were associated with primary diagnoses of soft tissue sarcoma (EAR = 101.50, 95% CI = 68.00 to 150. 
Cumulative Incidence Rates
We next analyzed the cumulative incidence rates for developing secondary sarcomas in the CCSS cohort. We found a cumulative incidence rate for the development of secondary sarcoma at * SIRs = standardized incidence ratios; EARs = excess absolute risks; O = observed; E = expected; CI = confidence interval; CNS = central nervous system. z scores were used. All statistical tests were two-sided. † EARs are per 100 000 person-years. ‡ P value from test of trend was <.001.
30 years after initial cancer diagnosis of 1.08% (95% CI = 0.78% to 1.37%) and at 30 years among patients in the cohort who did not receive radiation therapy of 0.5% ( Fig. 1, A ) . We then determined the cumulative incidence of secondary sarcomas by primary diagnoses ( Fig. 1, B ) . The cumulative incidence rates at 30 years were higher among survivors of sarcomas (2.18%, 95% CI = 1.32% to 3.03%) and among survivors of Hodgkin lymphoma (1.91%, 95% CI = 1.01% to 2.80%) than among survivors of all other cancers (0.62%, 95% CI = 0.31% to 0.92%).
Cox Model Risk Factor Analysis
To identify treatment-related and other risk factors associated with the development of secondary sarcomas, we performed a univariate analysis ( Table 4 ) , followed by a multivariable Cox regression analysis ( Table 5 ). In the univariate analysis, statistically significant associations were observed between the risk of secondary sarcomas and the primary diagnosis of any childhood cancer; family history of cancer in a first-degree relative; history of other secondary cancers; history of radiation therapy; or history of an exposure to chemotherapy, alkylator therapy, or anthracycline therapy (see Table 4 ). Using our a priori list of 12 covariates (i.e., age at primary diagnosis, sex, primary diagnosis, radiation exposure, chemotherapy exposure, platinum drug dose categories, epipodophyllotoxin dose categories, alkylator drug scores, anthracycline dose categories, history of other second malignant neoplasms, family history of cancer in a fi rst-degree relative, and treatment era), we performed a multivariable Cox regression analysis to assess the relative risks of secondary sarcomas. Exposure to radiation was associated with an increased risk of developing secondary sarcoma (RR = 3.1, 95% CI = 1.5 to 6.2), as expected. However, higher total dose exposures to anthracyclines (RR = 2.3, 95% CI = 1.2 to 4.3) or to alkylating agents (RR = 2.2, 95% CI = 1.1 to 4.6) continued to be associated with an increased risk of secondary sarcomas when radiation exposure was included in the regression model ( Table 5 ). Among patients with radiation exposure, a prior history of soft tissue sarcoma was associated with a high risk of developing secondary sarcoma (RR = 10.1, 95% CI = 4.7 to 21.8). Other primary diagnoses were also associated with increased risks (including renal tumors, RR = 6.3, 95% CI = 2.4 to 16.7; bone tumors, RR = 5.6, 95% CI = 2.3 to 13.9; Hodgkin lymphoma, RR = 5.4, 95% CI = 2.3 to 12.7; and central nervous system tumors, RR = 5.5, 95% CI = 2.0 to 14.8). A history of other secondary malignancies was associated with an increased risk of developing secondary sarcoma (RR = 2.2, 95% CI = 1.1 to 4.5). Lastly, the association between a history of cancer in a fi rstdegree relative and the development of a secondary sarcoma approached borderline statistical signifi cance (RR = 1.4, 95% CI = 0.9 to 2.1; P = .10).
Discussion
Our analysis of secondary sarcomas in childhood malignancy survivors is, to our knowledge, the largest study regarding this topic reported in the literature. Childhood cancer survivors overall had a ninefold increased risk of developing a secondary sarcoma compared with rates of sarcoma in the general population of a similar age. When we compa red those CCSS participants who developed a secondary sarcoma with those who did not, the development of secondary sarcoma was associated with previous radiation exposure, higher dose exposures of anthracyclines or alkylators, or a history of other secondary malignancies. The highest risks were observed among ; for 20 years, number of survivors at risk = 2039 and cumulative incidence = 0.24% (95% CI = 0.08% to 0.39%); for 30 years, number of survivors at risk = 238 and cumulative incidence = 0.46% (95% CI = 0.07% to 0.85%). History of radiation exposure (RT) curve: for 10 years, number of survivors at risk = 7775 and cumulative incidence = 0.37% (95% CI = 0.24% to 0.50%); for 20 years, number of survivors at risk = 5072 and cumulative incidence = 0.89% (95% CI = 0.68% to 1.10%); for 30 years, number of survivors at risk = 730 and cumulative incidence = 1.37% (95% CI = 0.97% to 1.78%). B ) Stratifi ed by primary diagnoses. Sarcoma curve: for 10 years, number of survivors at risk = 2231 and cumulative incidence = 0.71% (95% CI = 0.37% to 1.04%); for 20 years, number of survivors at risk = 1442 and cumulative incidence = 1.64% (95% CI = 1.12% to 2.16%); for 30 years, number of survivors at risk = 202 and cumulative incidence = 2.18% (95% CI = 1.32% to 3.03%). Hodgkin lymphoma curve: for 10 years, number of survivors at risk = 1758 and cumulative incidence = 0.75% (95% CI = 0.36% to 1.14%); for 20 years, number of survivors at risk = 1157 and cumulative incidence = 1.34% (95% CI = 0.81% to 1.87%); for 30 years, number of survivors at risk = 211 and cumulative incidence = 1.91% (95% CI = 1.01% to 2.80%). Other diagnoses curve: for 10 years, number of survivors at risk = 9283 and cumulative incidence = 0.10% (95% CI = 0.04% to 0.16%); for 20 years, number of survivors at risk = 5401 and cumulative incidence = 0.33% (95% CI = 0.21% to 0.45%); for 30 years, number of survivors at risk = 658 and cumulative incidence = 0.62% (95% CI = 0.31% to 0.92%).
survivors of pediatric soft tissue and bone sarcomas, renal tumors, and Hodgkin lymphoma. History of cancer in a first-degree relative approached borderline statistical significance ( P = .10) as a risk for developing secondary sarcomas. Secondary sarcomas occur at a young age and were the cause of death in more than one-third of the patients with secondary sarcomas.
Radiation therapy has been shown to induce bone and soft tissue sarcomas (19 -21) . Previous studies (10, 22 -29) have focused mainly on secondary bone sarcomas and have investigated radiation-related and other treatment-related risk factors. Results of these studies indicate that exposure to radiation and/or chemotherapy is associated with risk. The Late Effects Study Group, a multi-institution international consortium, analyzed data from 64 patients with secondary bone sarcoma and found an association between bone sarcoma and radiation dose (10) . An expanded group of 91 patients with secondary bone sarcomas in this cohort was analyzed in another study (22) , and results indicated that exposure to anthracycline chemotherapy was associated with increased risk. Similarly, the National Registry of Childhood Tumours in Britain used a case -control design to analyze 55 patients with bone cancer tumors among 3-year survivors of childhood cancer diagnosed between 1940 and 1983 (30) . This study found that an increased risk of bone cancers was associated with increased dose of radiation or increased alkylator dose exposure. In a smaller British and French survivor cohort (25) , among 32 patients with secondary osteosarcoma, risk of secondary osteosarcoma among survivors of childhood solid tumors was found to be linearly associated with the local dose of radiation and the concentration of alkylating agents received. In contrast, * RR = relative risk; CI = confidence interval; CNS = central nervous system; SMN = second malignant neoplasm. Boldface values are statistically significant. Chi-square tests were used. All statistical tests were two-sided. † For platinum drugs, alkylator drugs, and epiphyllotoxins, each subject was assigned a score of 0, 1, 2, or 3 for each drug, depending on whether the subject received no agent or fell into the lower, middle, or upper third of each distribution, respectively. a nested case -control study (26) in Nordic countries of 31 childhood cancer survivors with secondary sarcomas (including both bone and connective tissue tumors) found that exposure to radiation was the only treatment associated with risk. Our study is unique in that we could compare patients who developed secondary sarcomas with those who did not, that it includes the largest group of patients with secondary sarcomas described, and that it includes secondary sarcomas of all histologic subtypes. Our fi ndings are consistent with the known association between secondary sarcoma occurrence and radiation exposure; however, our fi ndings also indicate that the risk of secondary sarcomas is increased in patients who did not receive radiation therapy (SIR = 2.68, 95% CI = 2.04 to 6.64; EAR = 10.33, 95% CI = 4.00 to 21.76). Risks in our cohort were associated with a primary diagnosis of sarcoma, even after controlling for treatment with radiation and chemotherapy, indicating that survivors of primary sarcoma in childhood are at highest risk for a second cancer. This observation and the fi ndings that a prior history of secondary malignancy was associated with increased risk and that members of our cohort had an increased frequency of family history of cancer indicate that childhood cancer survivors who develop secondary sarcoma may have an increased familial risk for their cancers. Genetic analysis of DNA samples from these patients should clarify this possibility.
We demonstrated that an increased risk of secondary sarcomas was associated with both radiation therapy and increasing doses of alkylators or anthracyclines. This fi nding may be a consequence of confounding between higher doses of chemotherapy and higher doses of radiation because childhood cancers that require higher doses of anthracyclines and/or alkylators also often require high doses of radiation. Unfortunately, we could not establish a dose -effect relationship for radiation exposure by use of cohort methodology. Also, because only 23 patients did not receive radiation therapy, stratifi cation analyses were not feasible. Alternative explanations for our fi nding that high doses of alkylators and anthracyclines were associated with risk include the possibility that the carcinogenic effect of radiation is increased by chemotherapy or that chemotherapeutic agents may be independently tumorigenic, inducing DNA damage and subsequently sarcomas.
Our study had several limitations, and the interpretation of its results must be considered in light of these limitations. Given the small number of patients with secondary sarcomas, examination of the effects of race and geography, as well as other demographic factors, on risk was not feasible. Because all second malignant neoplasms were self-reported in the CCSS, underreporting may have infl uenced our results. Family history of cancer was also selfreported and so may have been inaccurate; we did not use medical records to confi rm such family histories. Finally, the analysis was limited to secondary sarcomas that were diagnosed 5 years or more after the primary cancer diagnosis; therefore, our study could not necessarily identify risks for earlier secondary sarcomas.
As the childhood cancer survivor population ages and expands in number, clinicians and researchers must carefully identify patients who are at risk for secondary morbidities, particularly for secondary cancers. Clinical factors associated with increased risk of secondary cancers appear to include prior radiotherapy, family history of cancer, other secondary cancers, prior history of childhood sarcoma, and prior treatment with high doses of alkylators and/or anthracyclines. Diagnosis of a sarcoma can sometimes be elusive because symptoms are often nonspecifi c. The clinician who is alert to a patient's prior history is in a better position to make an early, and possibly life-saving, diagnosis because early detection of these tumors is associated with decreased morbidity (29) . Moreover, development of screening techniques to detect a genetic predisposition to radiation sensitivity may lead to the identifi cation of populations at increased risk for secondary sarcoma. Finally, these at-risk individuals may form a group in whom chemoprevention strategies for secondary sarcomas in childhood cancer survivors might be tested.
